Pricing Log in Create free account
Saturday 17 October 2026 Export BCAB’s income statement to Excel — free account

BioAtla, Inc.

BCAB Healthcare Biotechnology

BioAtla, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 81.8% from fiscal 2024. In the quarter to June 2026, revenue grew 4,233.3%, EPS grew 101.7% and free cash flow grew 97.0%, each against the same quarter a year earlier.

1.36 0.06 +4.62%
Market cap
$2.9M
P/E
0.0×
Fwd P/E
−0.2×
Dividend yield
—
F-score
n/a
Altman Z
−70.06
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 16.90%

Capital & Financial Ratios $m

Market Cap 2.89
Revenue 17.75
Net Income (31.45)
Free Cash Flow (23.48)
Net Debt (1.54)
Current Ratio 0.20 (below 1: weak)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (0.19) (negative: loss-making)
P/S ratio 0.13
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth 25.00% (at or above 15%: strong)
Next Y EPS Growth 14.81%
Next Y revenue growth (50.00%) (below 0%: weak)
Next 5Y EPS Growth 6.69%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.6×, against a ten-year median of 1.6×; over the ten years it ranged from −202× in 2022 to 3,495× in 2021.
P/S against its own 10 years 1.23%
10-year low 10-year high
EV/Sales against its own 10 years 5.74%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 111 49 7 2
Receivables — — — 2
Inventory — — — —
Other — — — —
116 51 8 4
2023 2024 2025 Q'26
Payables 27 14 16 19
ST’ Debt — — — —
Other — — 4 —
28 15 22 21

Compound Annual Growth %

10y 5y 3y
Sales — (28.40%) 67.05%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 — 7 — — —
’25 — — — — 2
’24 — — 11 — 11
’21 — 0 — — 0
’20 0 0 0 0 0
’19 — — — 2 5
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (5) 0 — — —
’25 (16) (14) (10) (8) (48)
’24 (31) (19) (5) (17) (72)
’23 (23) (24) (27) (30) (104)
’22 (25) (17) (24) (24) (90)
’21 (15) (14) (13) (21) (62)
’20 (4) (3) (15) (14) (36)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (5) 0 — — —
’25 (16) (14) (10) (8) (48)
’24 (31) (19) (5) (17) (72)
’23 (23) (24) (27) (30) (104)
’22 (25) (17) (24) (24) (91)
’21 (15) (14) (13) (21) (63)
’20 (4) (3) (16) (14) (37)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (4.22) 0.27 — — —
’25 (13.00) (16.00) (13.50) (8.00) (50.50)
’24 (24.00) (22.00) (11.00) (15.00) (72.00)
’23 (29.00) (37.50) (35.00) (28.00) (129.00)
’22 (32.50) (38.50) (34.50) (31.50) (137.00)
’21 (28.00) (45.00) (34.00) (31.50) (138.00)
’20 (0.05) (0.18) (7.19) (205.51) (212.70)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — 1,357.50 936.00 100.50 62.00 28.50 12.00

Analyst estimates 2026–2028

Powerpack
High — — — — 2,193.00 3,831.50 1,024.50 441.00 201.00 71.50
People
People Employees — — — — 36 56 66 65 61 41
Revenue/emp, $m — — 0.00 0.00 0.01 0.00 0.00 0.00 0.18 0.05
Income, $m
Income, $m Revenue — — 11 5 0 0 — — 11 2
Gross margin, % — — 0.00 100.00 100.00 100.00 0.00 — 100.00 100.00
EBT — — (29) (30) (36) (95) (106) (123) (70) (60)
EBT margin, % — — (272.69) (574.13) (8,357.34) (38,160.80) 0.00 0.00 (634.33) (2,980.35)
Net income — 0 (29) (30) (36) (95) (106) (123) (70) (60)
Depreciation — — 1 1 1 1 1 1 1 0
Per share, $
Per share, $ Revenue — — 0.32 4.76 2.54 0.36 0.00 0.00 11.32 1.70
Earnings — — (0.84) (27.34) (212.70) (138.00) (137.00) (129.00) (72.00) (50.50)
Cash flow — — (1.05) (8.83) (215.50) (90.01) (116.15) (108.85) (74.05) (40.97)
Capex — — 0.00 (1.38) (3.50) (1.34) (0.34) (0.10) 0.00 0.00
Free cash flow — — (1.05) (10.21) (219.00) (91.35) (116.49) (108.95) (74.05) (40.97)
Book value — — (0.85) (51.29) 1,245.40 305.01 231.65 73.96 14.68 (30.76)
Shares, m — — 34 1 0 1 1 1 1 1
Valuation, ×
Valuation, × P/E — — 0.00 0.00 0.00 0.00 — — 0.00 0.00
P/S — — 953.36 953.36 668.31 1,149.85 — — 2.52 2.93
P/B — — 0.00 0.00 1.37 3.22 — — 2.01 0.00
EV/Sales — — 973.27 973.27 136.33 752.24 — — (0.87) 3.22
EV/FCF — — (76.04) (76.04) (1.58) (7.03) — — 0.14 (0.76)
Cash, $m
Cash, $m Operating cash flow — — (35) (10) (36) (62) (90) (104) (72) (48)
Capex — — (1) (2) (1) (1) 0 0 — —
Free cash flow — — (35) (11) (37) (63) (91) (104) (72) (48)
Balance, $m
Balance, $m Working capital — — 3 (22) 208 227 197 88 37 (14)
Total debt — — 15 18 1 5 4 — — —
Net debt — — 4 14 (238) (245) (216) (111) (49) (7)
Shareholders’ equity — — (28) (56) 210 211 180 71 14 (36)
Returns, %
Returns, % ROA — — (338.57) (221.24) (28.20) (38.21) (44.35) (71.49) (81.10) (179.95)
ROIC — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE — — 21.41 21.77 (112.27) (45.34) (54.44) (98.37) (164.30) 543.76
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

BioAtla, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
REVB Revelation Biosciences, Inc. $3.0M — (loss-making) — — n/m −35.29% (below 0%: shrinking) 0.00% 0.00% Compare
ARAV ARAVIVE, INC $3.0M — (loss-making) — (loss-making) −44.39% (below 0%: shrinking) n/m +48.19% (above 0%: growing) 100.00% (323.44%) Compare
DCOY Decoy Therapeutics Inc $2.9M 0.0× — (loss-making) −84.61% (below 0%: shrinking) n/m −212.47% (below 0%: shrinking) 100.00% (1,055.98%) Compare
MBIO Mustang Bio, Inc. $2.9M — (loss-making) — — n/m +27.78% (above 0%: growing) 0.00% 0.00% Compare
BCAB BioAtla, Inc. $2.9M — (loss-making) — (loss-making) +4,233.33% (above 0%: growing) n/m +97.03% (above 0%: growing) 100.00% 3.49%
ONCO Onconetix, Inc. $2.9M 0.0× — (loss-making) −83.94% (below 0%: shrinking) n/m −36.00% (below 0%: shrinking) 25.15% (15,969.59%) Compare
VIVS VivoSim Labs, Inc. $2.8M — (loss-making) — (loss-making) −51.35% (below 0%: shrinking) n/m +17.87% (above 0%: growing) 100.00% (15,327.78%) Compare
AFMDQ Affimed N.V. $2.8M — (loss-making) — (loss-making) −92.02% (below 0%: shrinking) n/m +46.95% (above 0%: growing) 100.00% (9,216.90%) Compare
HCWB HCW Biologics Inc. $2.8M — (loss-making) — (loss-making) +1,954.55% (above 0%: growing) n/m −20.84% (below 0%: shrinking) (69.25%) (2,335.03%) Compare
Median of peers $2.9M — — −67.64% — −1.49% 62.58% (1,695.50%)

All 614 Biotechnology stocks →

BioAtla, Inc. (BCAB) key facts

  • Concern: BioAtla, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 81.8% from fiscal 2024.
  • BioAtla, Inc. (BCAB) is a Biotechnology company in the Healthcare sector.
  • As of October 16, 2026, BCAB traded at $1.36, a market capitalization of $2.9 million.
  • Return on equity was 543.8% and debt-to-equity 0.00.
  • Its Altman Z-score is −70.06 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

BioAtla, Inc. (BCAB) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/BCAB · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com